What question did this study set out to answer?

To investigate the oncogenic consequences of constitutive insulin-like growth factor I receptor activation and evaluate targeted kinase inhibition in a novel animal model.

May 1, 2005Cancer ResearchOpen Access

Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor

View Full Paper

Ask AI

Bookmark

Authors

JCJoan M. CarboniBristol-Myers Squibb (United States)ALAdrian V. LeeUniversity of Pittsburgh DHDarryl L. HadsellChildren's Nutrition Research Center at Baylor College of Medicine

Discussion

Member takes

Implication

Preclinical study reveals rapid adenocarcinoma development in mice expressing constitutively active IGF-I receptor, highlighting its role in tumorigenesis and potential for targeted therapy.

Key Points

To investigate the oncogenic consequences of constitutive insulin-like growth factor I receptor activation and evaluate targeted kinase inhibition in a novel animal model.
Engineered transgenic mice expressing a homodimerization-activated fusion form of the insulin-like growth factor I receptor tyrosine kinase.
Assessed mammary gland architecture and monitored transgenic mice for spontaneous tumor formation over time.
Generated tumor-derived cell lines and xenografts to evaluate sensitivity to a novel small-molecule IGF-IR kinase inhibitor.
Transgenic mice exhibited aberrant mammary gland development and developed salivary and mammary adenocarcinomas as early as 8 weeks of age.
Transgenic tumor-derived cell lines and xenograft models demonstrated marked sensitivity to growth inhibition by the novel small-molecule IGF-IR kinase antagonist.

Cite This Study

Carboni et al. (2005) studied this question.

synapsesocial.com/papers/6a74598251ce19f0760934ec https://doi.org/10.1158/0008-5472.can-04-4602

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals rapid adenocarcinoma development in mice expressing constitutively active IGF-I receptor, highlighting its role in tumorigenesis and potential for targeted therapy.